Actively Recruiting
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
Led by Weizmann Institute of Science · Updated on 2025-07-20
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
W
Weizmann Institute of Science
Lead Sponsor
H
HaEmek Medical Center, Israel
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this study, the investigators will explore our protein-based platform assessing commensals potentially contributing to features of CD, while assessing the global composition and abundance of AMPs expressed in the GI tract under specific CD-relevant clinical contexts. This would enable us to (a) identify new commensals contributing to features of CD spectrum and various sub-types; (b) uncover the mechanistic basis of dysbiosis in CD (c) utilize the pipeline to develop new theranostic for disease exacerbation, complication and treatment responses; and (d) potentially enable future exploitation of novel AMP combinations, and their respective antimicrobial capacity to counteract dysbiosis in CD. Uncovering the proteomic manifestations of perturbed host-microbiome communications in CD will eventually enable the development and validation of clinical non-invasive surrogate markers, mechanistically determine causative drivers of CD, and potentially facilitate the development of novel therapeutic interventions.
CONDITIONS
Official Title
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Candidates for a medically-indicated diagnostic colonoscopy due to suspected new-onset Crohn's disease
- No prior medical or nutritional treatment for Crohn's disease
- For healthy controls: age- and gender-matched patients admitted for non-specific gastrointestinal complaints or routine colorectal cancer screening
You will not qualify if you...
- Prior diagnosis of inflammatory bowel disease with treatment
- Chronic gastrointestinal disorders such as celiac disease, eosinophilic esophagitis, collagenous gastritis, or autoimmune gastritis
- Type 1 or type 2 diabetes mellitus
- Past or present history of cancer
- Body mass index (BMI) over 30 kg/m2
- Use of systemic antibiotics or probiotics within 2 months before enrollment
- Use of steroids within 2 months before enrollment (excluding short courses of topical steroids)
- Previous major gastric or intestinal surgery
- Extensive involvement of non-ileal small intestine or colon or significant perianal disease
- Significantly stricturing or penetrating (fistulizing) disease at presentation
- Chronic treatment with oral or systemic immunosuppressive or anti-inflammatory drugs
- Primary immunodeficiency
- Pregnancy or breastfeeding within the last 6 months
- Serious medical conditions that may alter gut microbiome composition, such as autoimmune or rheumatologic disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Emek medical center
Afula, Israel
Actively Recruiting
Research Team
E
Eran Elinav, Prof
CONTACT
S
shimrit eliyahu miller
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here